Indications for ACE Inhibitors and ARBs in CKD
ACE inhibitors and ARBs are strongly indicated for CKD patients with albuminuria (moderately-to-severely increased, A2-A3) regardless of diabetes status, but provide no proven kidney protection in nonproteinuric CKD and should only be used for other indications like hypertension or heart failure in that population.
Clear Indications for RASi (ACEi/ARB) in CKD
Strong Recommendations (Start Treatment):
CKD with severely increased albuminuria (A3) without diabetes - G1-G4 stages 1, 2
- This is a Grade 1B recommendation (strong evidence)
CKD with moderately-to-severely increased albuminuria (A2-A3) with diabetes - G1-G4 stages 1, 2
- This is a Grade 1B recommendation (strong evidence)
Weaker Recommendations (Consider Treatment):
- CKD with moderately increased albuminuria (A2) without diabetes - G1-G4 stages 1, 2
- This is a Grade 2C recommendation (weaker evidence)
Other Acceptable Indications:
- CKD with normal/mildly increased albuminuria (A1) - Only when treating other specific conditions like hypertension or heart failure with reduced ejection fraction 1, 2
- Recent evidence from the CRIC study confirms that in nonproteinuric CKD, RASi provides no kidney protection benefit, though may offer mortality benefits for hypertension management 3
When ACEi/ARBs Are NOT Beneficial or Should Be Avoided
Absolute Contraindications:
- Combination therapy with ACEi + ARB + direct renin inhibitor (DRI) - Grade 1B recommendation to avoid 1, 2
- Dual or triple RAS blockade increases adverse events without additional benefit
Situations Requiring Dose Reduction or Discontinuation:
Discontinue or reduce dose if:
- Serum creatinine rises >30% within 4 weeks of initiation or dose increase 1, 2
- Symptomatic hypotension occurs 1, 2
- Uncontrolled hyperkalemia despite medical management 1, 2
- Advanced kidney failure (eGFR <15 ml/min/1.73 m²) with uremic symptoms 1, 2
Populations Where Benefits Are Uncertain:
- Nonproteinuric CKD (A1) - The CRIC study demonstrated no kidney protection in this population 3
- Advanced CKD (eGFR <30) - While the STOP-ACEi trial showed continuation didn't harm and trended toward lower ESKD rates, benefits are less clear 4
- Elderly patients with frailty, high fall risk, or limited life expectancy - Consider less intensive therapy 1
Critical Management Algorithm
Initiation Protocol:
- Start with highest approved tolerated dose (proven benefits achieved at these doses) 1, 2
- Check BP, creatinine, and potassium within 2-4 weeks 1, 2
Continuation Criteria:
- Continue therapy even when eGFR falls below 30 ml/min/1.73 m² unless contraindications develop 1
- Recent evidence supports continuation in advanced CKD unless specific adverse effects occur 4
Managing Hyperkalemia:
- First-line approach: Manage hyperkalemia medically rather than stopping RASi 1, 2
- Consider potassium binders and SGLT2 inhibitors as adjunctive therapy 4
- Only discontinue if hyperkalemia remains uncontrolled despite treatment
Common Pitfalls to Avoid
Don't prescribe RASi expecting kidney protection in nonproteinuric CKD - The evidence doesn't support this 3
Don't automatically discontinue when eGFR drops below 30 - Continue unless specific contraindications arise 1
Don't combine ACEi + ARB - This increases harm without benefit 1, 2
Don't stop RASi prematurely for mild hyperkalemia - Manage potassium first before discontinuing 1, 2
Don't underdose - Use maximum tolerated approved doses to achieve proven benefits 1, 2